Chroma Therapeutics
Chroma Therapeutics is focused on the R&D of novel small molecule drugs based on chromatin biology and cell accumulation.
Launch date
Employees
Market cap
-
Enterprise valuation
$98—147m (Dealroom.co estimates Jun 2009.)
Company register number 04066289
Winnersh England (HQ)
Financials
Estimates*
EUR | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
---|---|---|---|---|---|---|---|
Revenues | 6.2m | 20.4m | <1m | <1m | - | <1m | - |
% growth | (30 %) | 231 % | (100 %) | 1285 % | - | - | - |
EBITDA | 2.0m | 19.1m | (1.2m) | <1m | (<1m) | (<1m) | (<1m) |
% EBITDA margin | 33 % | 93 % | (2823 %) | 81 % | - | (3 %) | - |
Profit | (1.3m) | 25.7m | (22.2m) | (<1m) | (<1m) | (<1m) | (<1m) |
% profit margin | (21 %) | 126 % | (51263 %) | (111 %) | - | (1 %) | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | $1.9m | Seed | |
$18.0m | Series B | ||
$53.0m | Series C | ||
$24.5m | Series D | ||
$15.0m | Debt | ||
Total Funding | $97.4m |
Recent News about Chroma Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.